A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas

Journal of Neuro-Oncology

Volumn 117, Issue 1, 2014, Pages 93-101

  Raizer, Jeffrey J ^a   Grimm, Sean A ^a,d   Rademaker, Alfred ^b   Chandler, James P ^b   Muro, Kenji ^b,d   Helenowski, Irene ^b   Rice, Laurie ^a,e   McCarthy, Katie ^a   Johnston, Sandra K ^c   Mrugala, Maciej M ^c   Chamberlain, Marc ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d CENTRAL DUPAGE HOSPITAL   (United States)

^e Bend Memorial Clinic   (United States)

Author keywords

Chemotherapy; Meningioma; PDGF; PTK787; VEGF

Indexed keywords

VATALANIB;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DEHYDRATION; DEPRESSION; DIARRHEA; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG SAFETY; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPONATREMIA; INFECTION; LEUKOPENIA; MALE; MENINGIOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROSURGERY; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RADIOSURGERY; RASH; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRAIN; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MENINGIOMA; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PHTHALAZINES; PYRIDINES; SALVAGE THERAPY; TIME FACTORS;

EID: 84901592754     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1358-9     Document Type: Article

References (47)

1. Perry ALD, Scheithauer BW, Budka H, von Deimling A (2000) Meningeal tumors. WHO classification of tumors. Tumors of the nervous system. IARC, Lyon
2. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD (2009) Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 2001 - 2008). Neuro Oncol 11(6):853-860
3. Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY (2010) Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 96(2):211-217
4. Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE II, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS (2012) Phase II study of Gleevec(R) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol 106(2):409-415
5. Chamberlain MC, Tsao-Wei DD, Groshen S (2004) Temozolomide for treatment-resistant recurrent meningioma. Neurology 62(7):1210-1212
6. Chamberlain MC, Tsao-Wei DD, Groshen S (2006) Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol 78(3):271-276
7. Chamberlain MC, Johnston SK (2011) Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. J Neurooncol 104(3):765-771
8. Chamberlain MC (2012) Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. J Neurooncol 107(2):315-321
9. Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ (2012) Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol 109(1):187-193
10. Grunberg SM, Weiss MH (1990) Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. J Neurooncol 8(1):61-65
11. Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R (2006) Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 24(8):727-733
12. Grunberg SMRC, Townsend J, Ahmadi J, Feun L, Fredericks R, Russell C, Kabbinavar F, Barger GR, Stelzer KJ (2001) Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. Proc Am Soc Clin Oncol 20:222
13. Goodwin JW, Crowley J, Eyre HJ, Stafford B, Jaeckle KA, Townsend JJ (1993) A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol 15(1):75-77
14. Chamberlain MC, Glantz MJ, Fadul CE (2007) Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 69(10):969-973
15. Norden ADHS, Drappatz J, Phuphanich S, Reardon DA, Wong E, Plotkin SR, Lesser GJ, Raizer JJ, Batchelor T, Quant EC, Beroukhim R, Kaley TJ, Muzikansky A, Ciampa AS, Doherty LM, Smith KH, Gerard M, Sceppa C, Wen PY (2011) Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. J Clin Oncol 29(15):2040
16. Maxwell M, Galanopoulos T, Hedley-Whyte ET, Black PM, Antoniades HN (1990) Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products. Int J Cancer 46(1):16-21
17. Sanson M, Cornu P (2000) Biology of meningiomas. Acta Neurochir (Wien) 142(5):493-505
18. Machein MR, Plate KH (2000) VEGF in brain tumors. J Neurooncol 50(1-2):109-120
19. Nagashima G, Asai J, Suzuki R, Fujimoto T (2001) Different distribution of c-myc and MIB-1 positive cells in malignant meningiomas with reference to TGFs, PDGF, and PgR expression. Brain Tumor Pathol 18(1):1-5
20. Andersson U, Guo D, Malmer B, Bergenheim AT, Brannstrom T, Hedman H, Henriksson R (2004) Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol 108(2):135-142
21. Carroll RS, Black PM, Zhang J, Kirsch M, Percec I, Lau N, Guha A (1997) Expression and activation of epidermal growth factor receptors in meningiomas. J Neurosurg 87(2):315-323
22. Johnson M, Toms S (2005) Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy? J Neuropathol Exp Neurol 64(12):1029-1036
23. Ragel BT, Jensen RL (2010) Aberrant signaling pathways in meningiomas. J Neurooncol 99(3):315-324
24. Hultberg BM, Haselbacher G, Nielsen FC, Wulff BS, Gammeltoft S (1993) Gene expression of insulin-like growth factor II in human intracranial meningioma. Cancer 72(11):3282-3286
25. Ueba T, Takahashi JA, Fukumoto M, Ohta M, Ito N, Oda Y, Kikuchi H, Hatanaka M (1994) Expression of fibroblast growth factor receptor-1 in human glioma and meningioma tissues. Neurosurgery 34(2):221-225
26. Kaley TJWP, Schiff D, Karimi S, DeAngelis LM, Nolan C, Omuro A, Gavrilovic I, Norden A, Drappatz J, Purow B, Lieberman FS, Hariharan S, Abrey LE, Lassman AB (2010) Phase II trial of sunitinib (SU011248) for recurrent meningioma. Neurooncology 12(4):360-368
27. Horak P, Wohrer A, Hassler M, Hainfellner J, Preusser M, Marosi C (2012) Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis. J Neurooncol 109(2):323-330
28. Lamszus K, Lengler U, Schmidt NO, Stavrou D, Ergun S, Westphal M (2000) Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery 46(4):938-947
29. Yamasaki F, Yoshioka H, Hama S, Sugiyama K, Arita K, Kurisu K (2000) Recurrence of meningiomas. Cancer 89(5):1102-1110
30. Nagashima G, Aoyagi M, Yamamoto S, Wakimoto H, Tamaki M, Yamamoto K, Fujimoto T, Hirakawa K (2001) Involvement of disregulated c-myc but not c-sis/PDGF in atypical and anaplastic meningiomas. Clin Neurol Neurosurg 103(1):13-18
31. Todo T, Adams EF, Fahlbusch R, Dingermann T, Werner H (1996) Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. J Neurosurg 84(5):852-858
32. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60(8):2178-2189
33. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277-1280
34. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1-10
35. Chamberlain MC, Glantz MJ (2008) Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer 113(8):2146-2151
36. Newton HB, Scott SR, Volpi C (2004) Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br J Neurosurg 18(5):495-499
37. Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE (2002) Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg 97(2):341-346
38. Schrell UM, Rittig MG, Anders M, Koch UH, Marschalek R, Kiesewetter F, Fahlbusch R (1997) Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 86(5):840-844
39. Johnson DR, Kimmel DW, Burch PA, Cascino TL, Giannini C, Wu W, Buckner JC (2011) Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro Oncol 13(5):530-535
40. Choy W, Kim W, Nagasawa D, Stramotas S, Yew A, Gopen Q, Parsa AT, Yang I (2011) The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg Focus 30(5):E6
41. Johnson MD, O'Connell MJ, Pilcher W, Reeder JE (2010) Fibroblast growth factor receptor-3 expression in meningiomas with stimulation of proliferation by the phosphoinositide 3 kinase-Akt pathway. J Neurosurg 112(5):934-939
42. Barresi V (2011) Angiogenesis as a predictor of recurrence in meningiomas. J Neurooncol 101(1):169-170
43. Pistolesi S, Boldrini L, Gisfredi S, De Ieso K, Camacci T, Caniglia M, Lupi G, Leocata P, Basolo F, Pingitore R, Parenti G, Fontanini G (2004) Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study. Neuropathol Appl Neurobiol 30(2):118-125
44. Pfister C, Pfrommer H, Tatagiba MS, Roser F (2012) Vascular endothelial growth factor signals through platelet-derived growth factor receptor beta in meningiomas in vitro. Br J Cancer 107(10):1702-1713
45. Lou E, Sumrall AL, Turner S, Peters KB, Desjardins A, Vredenburgh JJ, McLendon RE, Herndon JE II, McSherry F, Norfleet J, Friedman HS, Reardon DA (2012) Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol 109(1):63-70
46. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, Avsar T, Li J, Murray PB, Henegariu O, Yilmaz S, Gunel JM, Carrion-Grant G, Yilmaz B, Grady C, Tanrikulu B, Bakircioglu M, Kaymakcalan H, Caglayan AO, Sencar L, Ceyhun E, Atik AF, Bayri Y, Bai H, Kolb LE, Hebert RM, Omay SB, Mishra-Gorur K, Choi M, Overton JD, Holland EC, Mane S, State MW, Bilguvar K, Baehring JM, Gutin PH, Piepmeier JM, Vortmeyer A, Brennan CW, Pamir MN, Kilic T, Lifton RP, Noonan JP, Yasuno K, Gunel M (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339(6123):1077-1080
47. Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, Ligon KL, Palescandolo E, Van Hummelen P, Ducar MD, Raza A, Sunkavalli A, Macconaill LE, Stemmer-Rachamimov AO, Louis DN, Hahn WC, Dunn IF, Beroukhim R (2013) Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45(3):285-289